Commonwealth Equity Services LLC Sells 2,389 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Commonwealth Equity Services LLC lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 11.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,714 shares of the company’s stock after selling 2,389 shares during the period. Commonwealth Equity Services LLC’s holdings in Takeda Pharmaceutical were worth $235,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TAK. Avantax Advisory Services Inc. bought a new position in Takeda Pharmaceutical during the fourth quarter worth $145,000. Farther Finance Advisors LLC grew its holdings in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after acquiring an additional 1,976 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Takeda Pharmaceutical by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company’s stock worth $69,000 after acquiring an additional 1,770 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 44.2% in the 4th quarter. Sequoia Financial Advisors LLC now owns 37,943 shares of the company’s stock valued at $502,000 after purchasing an additional 11,637 shares during the period. Finally, HighTower Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 1.5% during the 4th quarter. HighTower Advisors LLC now owns 124,439 shares of the company’s stock valued at $1,648,000 after purchasing an additional 1,852 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 2.2 %

Takeda Pharmaceutical stock opened at $14.37 on Thursday. The company has a market capitalization of $45.72 billion, a PE ratio of 35.93, a PEG ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.37. The firm’s fifty day moving average is $14.44 and its 200 day moving average is $13.91. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.